{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-100827","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.215682+00:00","generated_at":"2026-06-29T21:13:29.254590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport Q2 revenue $56.2M (+498% YoY); record trials, positive adjusted EBITDA","bullets":["Revenue $56.2M, up 498% YoY; organic growth 55%; Biopharma/Pharma up 431%.","Net loss $5.4M vs $5.8M loss a year ago; net loss per share $0.16 vs $0.15.","Adjusted EBITDA $5.9M vs ($2.5M) loss; gross margin 45.2% vs 54.6%.","Supporting 561 clinical trials and 8 commercial therapies; acquired F-airGate and CTSA in Q2.","Cash $349.4M after public offering; expects up to 9 MAA/BLA filings in H2 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-100827","json":"https://secwatch.observer/filing/0001104659-21-100827.json","markdown":"https://secwatch.observer/filing/0001104659-21-100827.md","text":"https://secwatch.observer/filing/0001104659-21-100827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465921100827/0001104659-21-100827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465921100827/tm2124288d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:13:29.254590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}